Date: February 14, 2025

To,
The Manager- Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Plot No. C/1, Block-G,
Bandra - Kurla Complex, Bandra (E),
Mumbai - 400051

SYMBOL: REMUS

Dear Sir/Madam,

Sub.: Integrated Filing (Governance) for the quarter ended on December 31, 2024

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, read with NSE Circular no. NSE/CML/2025/02 dated January 2, 2025, please find attached herewith the Integrated Filing (Governance) for the quarter ended December 31, 2024.

Kindly take the same on your records.

Thanking you.

Yours sincerely,
For, Remus Pharmaceuticals Limited

Deval Patel
Company Secretary and Compliance Officer
Membership No.: A60090

Encl: As Above

General information about company		
Scrip code	000000	
NSE Symbol	REMUS	
MSEI Symbol	NOTLISTED	
ISIN	INE0O5T01011	
Name of the entity	REMUS PHARMACEUTICALS LIMITED	
Date of start of financial year	01-04-2024	
Date of end of financial year	31-03-2025	
Reporting Quarter Type	Quarterly	
Date of Quarter Ending	31-12-2024	
Type of company	SME	
Whether Annexure I (Part A) of the SEBI Circular dated December 31, 2024 related to Compliance Report on Corporate Governance is applicable to the entity?	No	This is to inform you that our Company is fulfilling the non-applicability criteria as provided under Regulation 15(2)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, i.e., the Equity Shares of our Company are listed on the National Stock Exchange of India Limited (SME Emerge Platform). Therefore, in line with the exemption provided under Regulation 15(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company is not required to file quarterly/ half yearly/yearly Corporate Governance Report as per Regulation 27(2) of the SEBI (Listing Obligations and Disclosure Requirements), 2015.
Whether Annexure I (Part B) of the SEBI Circular dated December 31, 2024 related to Investor Grievance Redressal Report is Applicable to the entity?	Yes	
Whether Annexure I (Part C) of the SEBI Circular dated December 31, 2024 related to Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies is Applicable to the entity?	No	Not applicable during the quarter ended December 31, 2024
Whether Annexure I (Part D) of the SEBI Circular dated December 31, 2024 related to Disclosure of Imposition of Fine or Penalty is Applicable to the entity?	No	Not applicable during the quarter ended December 31, 2024
Whether Annexure I (Part E) of the SEBI Circular dated December 31, 2024 related to Disclosure of Updates to Ongoing Tax Litigations or Disputes is Applicable to the entity?	No	Not applicable during the quarter ended December 31, 2024
Is SCORE ID Available?	Yes	
SCORE Registration ID	COMR00724	
Reason For No SCORE ID	-	
Type of Submission	Original	
Remarks (website dissemination)	-	
Remarks for Exchange (not for Website Dissemination)	-	

Investor Grievance Details	
No. of investor complaints pending at the beginning of Quarter	0
No. of investor complaints received during the Quarter	0
No. of investor complaints disposed off during the Quarter	0
No. of investor complaints those remaining unresolved at the end of the Quarter	0

Remus Pharmaceuticals Limited
REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.
P: 079 2999 9857
E. remus@remuspharma.com | W. www.remuspharma.com
GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536